

Evaluation of Antimicrobial Stewardship Programs and Their Impact on Multidrug-Resistant Organisms in ICU Settings

Prof. Dr. Akira T. Morisaka
Professor of Clinical Medicine, Japan
amorisaka@kfu.ac.jp

Abstract

The emergence and rapid dissemination of multidrug-resistant organisms (MDROs) have become a major challenge in intensive care units (ICUs), contributing to increased morbidity, mortality, healthcare costs, and prolonged hospital stays. Excessive and inappropriate use of antimicrobial agents remains one of the primary drivers of antimicrobial resistance, particularly among critically ill patients who frequently require broad-spectrum antibiotic therapy. Antimicrobial Stewardship Programs (ASPs) have been developed to optimize antimicrobial utilization, improve patient outcomes, minimize adverse drug events, and reduce the development and transmission of resistant pathogens. This review evaluates the effectiveness of ASPs in ICU settings and examines their impact on controlling multidrug-resistant organisms. Evidence from recent clinical studies demonstrates that interventions such as prospective audit and feedback, formulary restriction, antibiotic de-escalation, rapid diagnostic testing, guideline-based prescribing, and multidisciplinary stewardship teams significantly improve antibiotic appropriateness and reduce antimicrobial consumption. Furthermore, successful ASP implementation has been associated with reductions in the incidence of methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), carbapenem-resistant *Enterobacteriales* (CRE), and multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter baumannii*. Despite these benefits, challenges including limited resources, diagnostic uncertainty, clinician resistance, and variability in stewardship practices continue to hinder optimal implementation. The integration of artificial intelligence, rapid molecular diagnostics, and real-time surveillance systems offers promising opportunities for enhancing stewardship effectiveness in critical care environments. Overall, antimicrobial stewardship represents a crucial strategy for combating antimicrobial resistance and improving patient safety in ICU settings. Continuous monitoring, multidisciplinary collaboration, and evidence-based interventions are essential for sustaining long-term reductions in MDRO prevalence and preserving the effectiveness of existing antimicrobial therapies.

Keywords

Antimicrobial Stewardship Program (ASP); Multidrug-Resistant Organisms (MDROs); Intensive Care Unit (ICU); Antimicrobial Resistance; Antibiotic Stewardship; Healthcare-Associated Infections; Methicillin-Resistant *Staphylococcus aureus* (MRSA); Vancomycin-Resistant *Enterococcus* (VRE); Carbapenem-Resistant *Enterobacteriales* (CRE); Antibiotic De-escalation; Infection Control; Critical Care Medicine; Rapid Diagnostics; Antimicrobial Optimization; Patient Safety.

1. Introduction

Antimicrobial resistance (AMR) has emerged as one of the most persistent threats to modern healthcare, with the problem becoming particularly serious in intensive care unit (ICU) environments. Critically ill patients are frequently exposed to invasive procedures, mechanical ventilation, central venous catheters, and prolonged hospitalization, all of which increase their vulnerability to healthcare-associated infections. At the same time, the severity and uncertainty associated with critical illness often lead clinicians to initiate broad-spectrum antimicrobial therapy before the causative pathogen and its susceptibility profile are known. Although this approach can be essential for preventing treatment delays in severe infections, repeated or unnecessarily prolonged exposure to antimicrobial agents can promote the selection of resistant microorganisms [1], [2].

Article Received: 09-01-2026

Article Revised: 28-02-2026

Article Accepted: 14-03-2026

Article Published: 21-03-2026

Citation: "Evaluation of Antimicrobial Stewardship Programs and Their Impact on Multidrug-Resistant Organisms in ICU Settings", *ijrgmh*, vol. 2, no. 1, pp. 44–58, March. 2026.

Copyright: © 2026 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

The ICU represents a complex ecological environment in which antimicrobial pressure, high patient turnover, cross-transmission, and the concentration of severely ill individuals can accelerate the emergence and dissemination of multidrug-resistant organisms (MDROs). Pathogens such as methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus* (VRE), carbapenem-resistant Enterobacterales (CRE), multidrug-resistant *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* can cause difficult-to-treat infections in critically ill patients. Infection with resistant organisms is associated with limited therapeutic choices, increased treatment complexity, prolonged hospitalization, greater healthcare expenditure, and poorer clinical outcomes [3], [4].

Antimicrobial stewardship has consequently become an important component of contemporary infection-management strategies. The central objective of an Antimicrobial Stewardship Program (ASP) is not simply to reduce antibiotic use, but to ensure that patients receive the appropriate antimicrobial agent, at the appropriate dose, through the appropriate route, and for an appropriate duration. Effective stewardship therefore requires a balance between providing immediate empirical treatment to patients with suspected serious infections and avoiding unnecessary antimicrobial exposure once additional clinical and microbiological information becomes available [5], [6].

The development of institutional stewardship programs has provided healthcare organizations with a structured approach for improving antimicrobial prescribing. Prospective audit and feedback, antimicrobial formulary restriction, preauthorization, dose optimization, intravenous-to-oral conversion, antibiotic time-outs, de-escalation, and development of evidence-based treatment guidelines are among the commonly employed interventions. These strategies can be implemented individually or as part of a coordinated multidisciplinary program involving infectious disease specialists, clinical pharmacists, microbiologists, infection-prevention professionals, intensivists, nurses, and other healthcare personnel [1], [2].

Evidence from hospital-based studies indicates that stewardship interventions can improve the appropriateness of antimicrobial prescribing while reducing unnecessary antimicrobial exposure. Davey et al. reported that interventions designed to improve antibiotic prescribing among hospitalized patients can influence prescribing behavior and may contribute to improvements in clinical management [7]. Similarly, Schuts et al. emphasized that stewardship programs should focus on measurable objectives, including appropriate antimicrobial selection, dosing, duration, and route of administration rather than relying solely on reductions in overall antibiotic consumption [8].

The potential effect of stewardship extends beyond antibiotic utilization. Reducing unnecessary antimicrobial pressure may help limit the selection and spread of resistant organisms within healthcare facilities. Baur et al. demonstrated that antibiotic stewardship interventions can contribute to reductions in antimicrobial resistance and healthcare-associated infections, supporting the concept that stewardship can complement conventional infection-prevention measures [9]. This is particularly relevant in ICUs, where resistant organisms can spread rapidly among patients who share healthcare personnel, equipment, and clinical environments.

Rapid microbiological and molecular diagnostic technologies have further expanded the potential of ICU stewardship. Conventional microbiological identification and susceptibility testing may require substantial time, whereas rapid diagnostic methods can provide clinically useful information earlier in the course of infection. When these technologies are combined with active stewardship interventions, clinicians may be able to narrow empirical therapy, discontinue unnecessary agents, or select more targeted treatment at an earlier stage [10].

Despite these advances, implementing antimicrobial stewardship in ICUs remains challenging. Critically ill patients frequently present with nonspecific signs of infection, and clinicians may have to initiate treatment before reliable microbiological evidence is available. Concerns regarding undertreatment, changing organ function, pharmacokinetic variability, polymicrobial infections, previous antimicrobial exposure, and local resistance patterns can complicate antimicrobial decision-making. Consequently, stewardship strategies designed for general hospital wards cannot always be transferred directly to the ICU without appropriate adaptation [11], [12].

Therefore, evaluating ASPs in ICU settings requires consideration of both antimicrobial-use outcomes and microbiological and clinical consequences. Measures such as defined daily doses, days of therapy, duration of antimicrobial exposure, guideline concordance, de-escalation rates, resistant-organism incidence, length of ICU stay, mortality, adverse drug events, and healthcare costs can provide a broader assessment of program effectiveness. A comprehensive evaluation should also consider whether reductions in antimicrobial exposure are achieved without compromising timely treatment of severe infections.

The present review therefore focuses on the role and effectiveness of antimicrobial stewardship programs in ICU settings, with particular attention to their influence on antimicrobial prescribing and multidrug-resistant organisms. It examines major stewardship interventions, their potential effects on resistant pathogens, implementation barriers, and emerging technologies that may strengthen stewardship practices. Understanding these factors is essential for developing sustainable ICU-based strategies capable of preserving antimicrobial effectiveness while maintaining safe and effective treatment for critically ill patients.

2. Literature Review

2.1 Development and Concept of Antimicrobial Stewardship

Dellit et al. established an important foundation for institutional antimicrobial stewardship by emphasizing the need for organized programs aimed at improving antimicrobial selection, dosing, route, and duration while achieving favorable patient outcomes. Their guidelines highlighted interventions such as prospective audit, feedback, formulary restriction, education, and development of evidence-based treatment recommendations. The framework remains particularly relevant to ICU practice because antimicrobial decisions in critically ill patients frequently need to be reassessed as microbiological and clinical information becomes available [1].

Barlam et al. subsequently expanded the evidence base for hospital antibiotic stewardship and emphasized that successful programs require coordinated interventions rather than isolated educational activities. Their recommendations placed considerable importance on prospective audit and feedback and preauthorization while also recognizing the contribution of pharmacy expertise, infectious disease consultation, and measurement of prescribing outcomes. In an ICU environment, these approaches can facilitate rapid reassessment of empirical treatment and encourage modification of therapy when the patient's clinical condition and laboratory findings become clearer [2].

2.2 Stewardship as a Component of Quality Patient Care

Dyar et al. described antimicrobial stewardship as a systematic effort to measure and improve antimicrobial use. Their work emphasized that stewardship should not be interpreted simply as antibiotic restriction. Instead, the fundamental objective is to optimize antimicrobial therapy for individual patients while minimizing unintended consequences associated with antimicrobial exposure. This distinction is particularly important in critical care because inappropriate reduction of therapy in patients with severe infections could be harmful, whereas unnecessary continuation of broad-spectrum treatment can increase resistance and drug-related complications [3]. Fishman discussed antimicrobial stewardship as a structured healthcare strategy involving appropriate antimicrobial prescribing, monitoring, and intervention. The concept recognizes that antimicrobial decisions influence not only individual patients but also the wider hospital microbial environment. In the ICU, where antimicrobial consumption is often high and resistant pathogens are concentrated, this ecological perspective provides a strong rationale for establishing dedicated stewardship processes and continuous review of antimicrobial therapy [4].

2.3 Evidence for Stewardship Interventions in Hospitals

Davey et al. evaluated interventions intended to improve antibiotic prescribing among hospitalized patients and found that stewardship interventions can modify prescribing practices and improve antibiotic use. Their findings support the use of structured interventions rather than relying exclusively on prescriber awareness or voluntary changes in practice. For ICUs, the implication is that antimicrobial review should be integrated into routine clinical workflows, allowing therapy to be reassessed as microbiological results, clinical response, and diagnostic information develop [5].

Schuts et al. examined the evidence surrounding hospital antimicrobial stewardship objectives and emphasized that appropriate antimicrobial therapy involves several interconnected dimensions, including drug selection, dosage, administration route, and treatment duration. Their analysis reinforces the importance of measuring stewardship performance using multiple indicators rather than antibiotic consumption alone. Such an approach is especially useful in ICUs, where a reduction in antibiotic use without adequate assessment of treatment outcomes may not accurately represent program effectiveness [6].

2.4 Clinical and Economic Benefits

Karanika et al. examined clinical and economic outcomes associated with antimicrobial stewardship programs and reported evidence supporting beneficial effects across several healthcare outcomes. Their analysis demonstrated that stewardship may produce value not only through changes in antimicrobial prescribing but also through reductions in avoidable antimicrobial expenditure and improvements in selected clinical measures. In resource-constrained healthcare environments, these findings are relevant because stewardship programs may provide both patient-safety benefits and opportunities for more efficient use of healthcare resources [7].

MacDougall and Polk described antimicrobial stewardship programs as organized approaches for improving antimicrobial use across healthcare systems. They highlighted the importance of combining antimicrobial policy, education, monitoring, and clinical intervention to achieve sustainable improvements. Their work also demonstrated that stewardship is most effective when supported institutionally and incorporated into routine clinical practice rather than functioning as an isolated activity. This principle is highly applicable to ICUs, where rapid treatment decisions require close interaction between stewardship personnel and critical-care teams [8].

2.5 Rapid Diagnostics and Stewardship

Timbrook et al. investigated the effect of rapid diagnostic testing when integrated with antimicrobial stewardship and demonstrated that molecular diagnostic information can strengthen antimicrobial optimization. Rapid identification of pathogens and resistance markers can provide clinicians with actionable information considerably earlier than conventional diagnostic workflows. In ICU patients, where delays in appropriate therapy may be associated with serious consequences, combining rapid diagnostics with pharmacist or infectious disease review can facilitate earlier escalation when required and earlier de-escalation when broad-spectrum therapy is no longer justified [9].

2.6 Antimicrobial Stewardship in Critical Care

Bassetti et al. discussed the distinctive challenges associated with antimicrobial stewardship in intensive care. They emphasized that critically ill patients often require immediate empirical therapy because delayed treatment of serious infection can have severe consequences. At the same time, critical illness produces considerable diagnostic uncertainty and physiological changes that influence antimicrobial pharmacokinetics and pharmacodynamics. Consequently, ICU stewardship requires a dynamic approach in which empirical treatment is initiated promptly but subsequently reassessed using microbiological findings, clinical response, local resistance data, and patient-specific characteristics [10].

Kollef and Micek examined the role of antimicrobial stewardship programs specifically within intensive care units and emphasized the need to balance early effective therapy against unnecessary antimicrobial exposure. Their work supports interventions such as antibiotic time-outs, de-escalation, pharmacokinetic optimization, and close collaboration between intensivists, infectious disease specialists, and pharmacists. They also highlighted the importance of considering local epidemiology and patient-specific risk factors when developing ICU antimicrobial policies, since resistant-pathogen patterns can vary substantially between institutions [11].

2.7 Stewardship, Resistance, and Multidrug-Resistant Organisms

Baur et al. evaluated the relationship between antimicrobial stewardship interventions and antimicrobial resistance and found evidence that stewardship can reduce resistance and healthcare-associated infections. Their findings are particularly important for ICU settings because high antimicrobial exposure can create strong selective pressure favoring resistant organisms. Effective stewardship can therefore function as an important complement to infection-prevention practices by reducing unnecessary antimicrobial pressure while promoting more targeted therapy [12].

2.8 Overall Research Gap

The literature demonstrates substantial support for antimicrobial stewardship as an effective strategy for improving antimicrobial utilization and potentially reducing antimicrobial resistance. However, the ICU presents unique clinical and operational circumstances that make stewardship considerably more complex than routine inpatient antibiotic management. Severe illness, empirical treatment requirements, rapidly changing organ function, polymicrobial infections, prior antimicrobial exposure, and limited diagnostic certainty can influence the success of individual stewardship interventions.

Furthermore, the impact of ASPs on specific MDROs may differ according to the intervention used, local antimicrobial consumption, infection-control practices, diagnostic capacity, and baseline resistance patterns. Consequently, antimicrobial consumption alone may not provide a complete assessment of stewardship success. Future evaluations should combine antimicrobial-use indicators with microbiological outcomes, clinical outcomes, patient-safety measures, and economic indicators. The increasing availability of rapid molecular diagnostics, electronic prescribing systems, real-time resistance surveillance, and data-driven decision-support technologies also creates opportunities for developing more responsive ICU stewardship models.

3. METHODOLOGY

3.1 Study Design and Literature Search

The present study adopted a structured literature review approach to evaluate the effectiveness of Antimicrobial Stewardship Programs (ASPs) in intensive care unit (ICU) settings, with particular emphasis on antimicrobial optimization and multidrug-resistant organisms (MDROs). Relevant literature was identified from major biomedical and multidisciplinary databases, including PubMed/MEDLINE, Scopus, Web of Science, ScienceDirect, and Google Scholar. The search focused on antimicrobial stewardship, antibiotic prescribing, ICU and critical-care infections, antimicrobial resistance, MDROs, antibiotic de-escalation, rapid diagnostics, and stewardship interventions. Established guidelines and major publications on antimicrobial stewardship were also considered [1], [2], [6], [28], [30].

3.2 Selection and Evaluation of Literature

Relevant peer-reviewed studies, systematic reviews, clinical guidelines, and other scientific publications addressing antimicrobial stewardship in hospitalized and critically ill patients were considered. Particular attention was given to evidence concerning prospective audit and feedback, antimicrobial restriction, de-escalation, guideline-based prescribing, dose optimization, rapid diagnostic testing, and multidisciplinary stewardship teams [1], [5], [10]. Studies involving important ICU-associated MDROs, including MRSA, VRE, CRE, multidrug-resistant *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, were also considered [11], [17], [35]. Publications that were unrelated to antimicrobial stewardship, antimicrobial resistance, or critical-care infection management were excluded.

3.3 Data Synthesis and Outcome Assessment

The selected literature was evaluated according to the type of stewardship intervention and its reported influence on antimicrobial use, prescribing appropriateness, treatment modification, MDRO occurrence, healthcare-associated infections, and relevant patient outcomes. The evidence was synthesized thematically rather than presenting detailed individual study data. Particular consideration was given to the relationship between antimicrobial optimization and resistance control, while recognizing that MDRO trends may also be influenced by infection-prevention practices, local resistance patterns, diagnostic capacity, and ICU characteristics [6], [8], [17], [24]. Economic and patient-safety outcomes were considered where relevant [7], [25]. This approach provided an overall assessment of the contribution of ASPs to appropriate antimicrobial use and MDRO control in critical-care environments.

4. Major Antimicrobial Stewardship Interventions In Icu Settings

4.1 Prospective Audit, Feedback, and Antimicrobial Restriction

Prospective audit and feedback is one of the commonly used approaches in antimicrobial stewardship. It involves reviewing antimicrobial therapy and providing recommendations to clinicians regarding continuation, modification, de-escalation, or discontinuation of treatment. In ICU settings, this approach can support timely reassessment of empirical therapy as clinical and microbiological information becomes available. Formulary restriction and preauthorization can additionally help control unnecessary use of selected broad-spectrum or reserve antimicrobials [1], [2].

4.2 Antibiotic De-escalation and Guideline-Based Therapy

Antibiotic de-escalation is particularly important in critically ill patients because treatment is frequently initiated with broad-spectrum coverage when the causative organism is not yet established. Once microbiological results and clinical response provide greater certainty, therapy can be narrowed or unnecessary agents discontinued. Evidence indicates that structured stewardship interventions can improve the appropriateness of antimicrobial prescribing while supporting more rational treatment practices [5], [6]. Development and implementation of local antimicrobial guidelines can further assist clinicians in selecting appropriate agents according to infection type, patient characteristics, and local resistance patterns [8].

4.3 Multidisciplinary Stewardship and Rapid Diagnostics

Effective ICU stewardship generally requires collaboration among intensivists, infectious disease specialists, clinical pharmacists, microbiologists, infection-control professionals, nurses, and other members of the healthcare team. Such multidisciplinary involvement allows antimicrobial decisions to be integrated with clinical assessment, microbiological findings, and infection-prevention practices [11], [32]. Rapid diagnostic technologies can further strengthen this process by providing earlier information about pathogens and resistance characteristics, thereby supporting more timely modification of empirical antimicrobial therapy [10]. The combination of rapid diagnostics with active stewardship intervention has considerable potential to improve antimicrobial optimization in critically ill patients.




Figure 1: Antimicrobial Stewardship Program Framework in ICU

5. Impact Of Antimicrobial Stewardship Programs On Multidrug-Resistant Organisms

5.1 Effect on Antimicrobial Resistance

Antimicrobial stewardship can influence the development and spread of antimicrobial resistance by reducing unnecessary exposure to broad-spectrum and prolonged antibiotic therapy. **Baur et al.** reported that stewardship interventions were associated with reductions in antimicrobial resistance and healthcare-associated infections, supporting the role of optimized antimicrobial use as an important component of resistance-control strategies [17]. Similarly, **Schuts et al.** emphasized that appropriate selection, dosing, route, and duration of antimicrobial therapy are essential components of effective stewardship [6].

5.2 Influence on Major ICU-Associated MDROs

ICUs are particularly vulnerable to MDROs such as MRSA, VRE, CRE, multidrug-resistant *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*. **Bassetti et al.** highlighted the importance of stewardship in managing resistant pathogens in critically ill patients, particularly through appropriate empirical treatment followed by reassessment and optimization [11]. **Kollef and Micek** similarly emphasized that ICU stewardship should balance the need for rapid effective treatment with efforts to minimize unnecessary antimicrobial exposure, particularly when resistant organisms are suspected [12]. The appropriate use of antimicrobial therapy, together with infection-control measures, can therefore contribute to limiting the selection and transmission of resistant organisms [24].




Figure 2: ICU Antibiotic De-escalation Process

5.3 Role of De-escalation in MDRO Control

De-escalation represents an important mechanism through which ASPs may reduce antimicrobial pressure within ICU environments. **Tamma et al.** emphasized the importance of reassessing antibiotic therapy rather than continuing broad-spectrum treatment automatically when additional clinical and microbiological information becomes available [14]. **Teshome et al.** demonstrated the relevance of antimicrobial exposure duration to the development of resistance, supporting efforts to avoid unnecessarily prolonged exposure to antipseudomonal therapy [31]. Consequently, timely narrowing or discontinuation of antimicrobial treatment may contribute to reducing selective pressure and supporting long-term MDRO control.

5.4 Integration with Infection Prevention

Antimicrobial stewardship should not be considered independently from infection-prevention and control measures. **Vincent et al.** demonstrated the substantial burden of infection among ICU patients, highlighting the importance of coordinated approaches to infection management [22]. **Magill et al.** further demonstrated the continuing significance of healthcare-associated infections, emphasizing the need for comprehensive prevention strategies [23]. Therefore, the control of MDROs is most effectively approached through the combined implementation of antimicrobial stewardship, appropriate diagnostic practices, environmental hygiene, hand hygiene, surveillance, and infection-control procedures [17], [24].

Table 1. Influence of Antimicrobial Stewardship Programs on Multidrug-Resistant Organisms in ICU Settings

Stewardship Intervention	Target/Area	Potential Impact on MDROs	Key Supporting References
Prospective audit and feedback	Antimicrobial prescribing	Improves appropriateness of antibiotic therapy and reduces unnecessary exposure	[1], [2]
Formulary restriction and preauthorization	Broad-spectrum/reserve antibiotics	Limits inappropriate use and reduces antimicrobial selection pressure	[1], [2]
Antibiotic de-escalation	Empirical broad-spectrum therapy	Reduces unnecessary antimicrobial exposure following clinical or microbiological reassessment	[14], [31]
Guideline-based prescribing	Empirical and targeted treatment	Promotes appropriate antimicrobial selection according to infection and resistance patterns	[6], [8]

Rapid diagnostic testing	Early pathogen and resistance identification	Supports earlier modification and narrowing of antimicrobial therapy	[10]
Multidisciplinary stewardship	ICU antimicrobial management	Strengthens coordinated antimicrobial decision-making and resistance control	[11], [32]
Stewardship with infection-control measures	MRSA, VRE, CRE and other MDROs	Supports reduction in selection and transmission of resistant organisms	[17], [22], [24]

Table interpretation: The available evidence indicates that ASPs can contribute to MDRO control primarily by improving antimicrobial selection and reducing unnecessary antimicrobial pressure. Their effectiveness is enhanced when stewardship activities are integrated with rapid diagnostics, multidisciplinary clinical review, and infection-prevention measures [10], [17], [24].

6. Clinical And Patient Outcomes Associated With Antimicrobial Stewardship

6.1 Patient Safety and Treatment Outcomes

Antimicrobial stewardship programs aim to improve the quality of antimicrobial treatment without compromising timely management of serious infections. **Schuts et al.** emphasized that appropriate antimicrobial selection, dosing, route, and duration are central to achieving optimal treatment outcomes [6]. In ICU settings, where patients may deteriorate rapidly, stewardship interventions therefore need to support appropriate empirical treatment while ensuring that therapy is reassessed as clinical and microbiological information becomes available [11].




Figure 3: ASP Impact on Multidrug-Resistant Organisms

6.2 Length of Stay and Mortality

Appropriate antimicrobial management may contribute to improved clinical outcomes and more efficient use of ICU resources. **Karanika et al.** reported beneficial clinical and economic outcomes associated with antimicrobial stewardship programs [7]. However, the effect of ASPs on mortality and length of hospital or ICU stay may vary according to patient characteristics, infection severity, pathogen type, and the specific stewardship intervention implemented. Consequently, stewardship should not be evaluated solely on mortality reduction but as part of a broader strategy for improving antimicrobial management and patient safety [38].

6.3 Reduction of Adverse Effects and Unnecessary Exposure

Unnecessary or prolonged antimicrobial therapy can expose critically ill patients to drug-related adverse effects and other complications. **Tamma et al.** emphasized the importance of reassessing antimicrobial treatment rather than continuing therapy without clinical justification [14]. Similarly, **Davey et al.** demonstrated that interventions designed to improve antibiotic prescribing can lead to more appropriate antimicrobial use among hospitalized patients [5]. De-escalation and discontinuation of unnecessary therapy may therefore reduce avoidable antimicrobial exposure while maintaining effective treatment.

6.4 Economic and Healthcare Benefits

Antimicrobial stewardship can also provide economic benefits through more efficient antimicrobial utilization and prevention of avoidable treatment-related costs. **Dik et al.** highlighted the importance of evaluating the financial consequences of stewardship programs, while **Karanika et al.** reported evidence of favorable economic outcomes associated with ASP implementation [25], [7]. In ICU environments, these benefits may be particularly relevant because prolonged antimicrobial therapy, resistant infections, and extended hospitalization can place substantial demands on healthcare resources.

6.5 Overall Clinical Significance

Overall, ASPs can contribute to improved antimicrobial prescribing, reduced unnecessary exposure, enhanced patient safety, and more efficient healthcare delivery. Their clinical value is greatest when antimicrobial optimization is combined with appropriate diagnostic evaluation, infection prevention, and continuous multidisciplinary review [2], [11]. Thus, stewardship should be regarded as a patient-safety and quality-improvement strategy rather than simply a mechanism for reducing antibiotic consumption.

Table 2. Clinical and Patient Outcomes Associated with Antimicrobial Stewardship Programs

Outcome Area	Effect of Antimicrobial Stewardship	Clinical Significance	References
Antimicrobial prescribing	Improves selection, dosage, route, and duration of therapy	Promotes appropriate treatment	[5], [6]
Patient safety	Reduces unnecessary antimicrobial exposure	May minimize avoidable drug-related complications	[14]
Treatment optimization	Encourages timely reassessment and de-escalation	Supports targeted antimicrobial therapy	[2], [11]
Length of hospital/ICU stay	May support more efficient patient management	Can reduce healthcare resource utilization	[7], [38]
Mortality	May support favorable outcomes when appropriate therapy is maintained	Requires consideration of infection severity and patient factors	[7], [11]
Antimicrobial adverse effects	Reduced unnecessary or prolonged therapy	May decrease avoidable medication-related harm	[5], [14]
Healthcare-associated infections	Stewardship may complement infection-prevention measures	Supports broader infection-control objectives	[17], [23]
Healthcare expenditure	More rational antimicrobial utilization	May reduce avoidable treatment costs	[7], [25]
MDRO control	Reduces unnecessary antimicrobial selection pressure	Supports prevention of antimicrobial resistance	[17], [24]

Table interpretation: ASPs can influence several interconnected clinical outcomes by promoting appropriate antimicrobial use while reducing unnecessary exposure. Their overall benefit is strengthened when antimicrobial optimization is combined with infection prevention, diagnostic support, and multidisciplinary clinical decision-making [2], [11], [17].

7. Challenges And Limitations In Implementing Antimicrobial Stewardship Programs In Icu Settings

7.1 Clinical and Diagnostic Challenges

Implementation of ASPs in ICUs is complicated by the severity and complexity of critically ill patients. Empirical broad-spectrum antibiotics are often initiated before definitive microbiological results are available because delays in appropriate treatment can adversely affect patients with serious infections. **Bassetti et al.** highlighted the difficulty of balancing immediate antimicrobial treatment with subsequent optimization in critically ill populations

[11]. Diagnostic uncertainty, polymicrobial infections, changing clinical conditions, and variations in antimicrobial pharmacokinetics can further complicate stewardship decisions [32].

7.2 Clinician-Related and Organizational Barriers

Successful stewardship requires active cooperation between clinicians and stewardship teams. Concerns about treatment failure, reluctance to modify established antibiotic therapy, workload, and differences in prescribing practices may limit implementation. **Howard et al.** identified considerable variation in the development and implementation of antimicrobial stewardship practices internationally, demonstrating the influence of institutional resources and organizational structure [16]. **Pulcini et al.** also emphasized the importance of clearly defined stewardship structures and core elements for effective implementation across different healthcare settings [34].

7.3 Resource and Infrastructure Limitations

The effectiveness of ICU stewardship may be affected by limited availability of infectious disease specialists, clinical pharmacists, microbiological services, rapid diagnostic technologies, and antimicrobial surveillance systems. **Basseti et al.** noted that resource availability and institutional infrastructure are important considerations when implementing stewardship in critical-care environments [11]. In settings with limited laboratory and technological support, timely antimicrobial optimization may be more difficult to achieve.

7.4 Variability in Resistance Patterns

Antimicrobial resistance varies considerably between hospitals, ICUs, geographical regions, and patient populations. Consequently, stewardship recommendations developed for one institution may not always be directly applicable to another. **Taconelli et al.** highlighted the global importance of priority resistant pathogens and the need for context-specific approaches to antimicrobial resistance [35]. Local antimicrobial susceptibility data and continuous surveillance are therefore important for developing appropriate ICU prescribing strategies.

7.5 Limitations in Measuring Program Effectiveness

Assessment of ASP effectiveness can also be challenging because antimicrobial consumption and resistance patterns are influenced by multiple factors. Infection-control practices, patient characteristics, changes in prescribing policies, diagnostic methods, and local epidemiology may affect observed outcomes independently of stewardship interventions. **Dik et al.** emphasized the importance of selecting appropriate indicators for measuring stewardship impact rather than relying on a single outcome measure [36]. Therefore, comprehensive evaluation should consider antimicrobial use, resistance, clinical outcomes, patient safety, and economic consequences together.

8. Expected Outcomes And Results

8.1 Antimicrobial Utilization

The expected findings indicate that implementation of ASPs in ICU settings can improve the appropriateness of antimicrobial prescribing. Interventions such as prospective audit and feedback, guideline-based prescribing, antimicrobial restriction, and de-escalation are expected to reduce unnecessary antimicrobial exposure while maintaining appropriate treatment for serious infections [1], [2], [5]. The overall effect is expected to be more rational selection and duration of antimicrobial therapy.

8.2 Multidrug-Resistant Organisms

ASPs are expected to contribute to better control of MDROs by reducing unnecessary antimicrobial pressure. Evidence from previous research indicates that stewardship interventions can be associated with reductions in antimicrobial resistance and healthcare-associated infections [17]. The expected benefit is particularly relevant for organisms such as MRSA, VRE, CRE, multidrug-resistant *Pseudomonas aeruginosa*, and *Acinetobacter baumannii*, although the magnitude of improvement may vary according to local resistance patterns and infection-control practices [11], [24].

8.3 Clinical and Economic Outcomes

The review is expected to demonstrate that appropriate antimicrobial management may support favorable patient outcomes without compromising effective infection treatment. Reduced unnecessary antibiotic exposure may also decrease antimicrobial-related complications and contribute to more efficient healthcare resource utilization [6], [7]. Stewardship programs may additionally provide economic benefits through improved antimicrobial utilization and reduction of avoidable treatment costs [25].

Table 3. Expected Outcomes of Antimicrobial Stewardship Programs in ICU Settings

Outcome Parameter	Expected Effect	Overall Expected Benefit
Antimicrobial prescribing	Improved appropriateness	More rational therapy
Broad-spectrum antibiotic use	Reduced unnecessary exposure	Lower selection pressure
Antibiotic de-escalation	Increased appropriate modification	More targeted treatment
MDRO occurrence	Potential reduction	Improved resistance control
Healthcare-associated infections	Potential reduction	Improved infection prevention
Adverse antimicrobial effects	Reduced unnecessary exposure	Improved patient safety
ICU/hospital resource use	More efficient management	Potential economic benefit
Treatment quality	Better alignment with clinical and microbiological findings	Improved antimicrobial optimization

9. Discussion

The findings synthesized from the available literature indicate that antimicrobial stewardship has an important role in improving antimicrobial management within ICU environments. The principal value of ASPs is not simply the reduction of antibiotic consumption but the promotion of appropriate treatment throughout the course of critical illness. **Dellit et al.** and **Barlam et al.** emphasized structured stewardship interventions, including prospective audit, feedback, antimicrobial restriction, and evidence-based prescribing, as important mechanisms for optimizing antimicrobial use [1], [2].

The review further indicates that de-escalation is an important component of ICU antimicrobial management. Critically ill patients often receive broad empirical therapy because of the risk associated with delayed treatment of severe infections. Once microbiological and clinical information becomes available, however, continued use of unnecessarily broad therapy may increase antimicrobial selection pressure. **Tamma et al.** emphasized the importance of reassessing antimicrobial treatment rather than continuing therapy without appropriate clinical justification [14].

The relationship between stewardship and antimicrobial resistance is particularly significant. **Baur et al.** demonstrated that stewardship interventions can contribute to reductions in antimicrobial resistance and healthcare-associated infections [17]. This supports the view that optimizing antimicrobial exposure may have benefits extending beyond individual patient management. However, resistance is influenced by several factors, and ASPs should therefore operate alongside infection-prevention and control measures [22], [24].

The literature also suggests that successful stewardship requires multidisciplinary participation. **Kollef and Micek** emphasized the importance of collaboration among intensivists, infectious disease specialists, pharmacists, microbiologists, and other healthcare professionals in developing effective ICU stewardship practices [12]. Such collaboration is particularly important because antimicrobial decisions in critically ill patients may change rapidly in response to clinical deterioration, microbiological findings, organ dysfunction, or treatment response.

Another important consideration is the effect of ASPs on patient safety. Concerns that reducing antibiotic exposure could result in inadequate treatment need to be balanced against the recognized risks of unnecessary or prolonged antimicrobial therapy. **Schuts et al.** emphasized that appropriate antimicrobial therapy involves the correct drug, dose, route, and duration rather than simply maximizing antimicrobial coverage [6]. Therefore, successful stewardship should seek to maintain effective treatment while minimizing avoidable exposure.

Overall, the evidence supports ASPs as an important component of ICU quality improvement and antimicrobial resistance control. Nevertheless, differences in institutional resources, resistance patterns, clinical practices, diagnostic capacity, and infection-control systems can influence program effectiveness. **Dik et al.** highlighted the importance of using multiple indicators when evaluating stewardship outcomes rather than relying on antimicrobial consumption alone [36]. A comprehensive evaluation should therefore consider antimicrobial utilization, MDRO trends, clinical outcomes, patient safety, and economic consequences together.

Table 4. Summary of Discussion Findings

Study Aspect	Overall Finding	Interpretation
Antimicrobial optimization	Generally favorable	ASPs improve prescribing practices
De-escalation	Beneficial	Supports targeted treatment
Antimicrobial resistance	Potential reduction	Lower antimicrobial pressure may support MDRO control

Patient safety	Generally favorable	Avoids unnecessary antimicrobial exposure
Clinical outcomes	Potential improvement	Benefits depend on patient and ICU characteristics
Economic outcomes	Potentially favorable	More efficient antimicrobial utilization
Multidisciplinary approach	Important	Improves implementation and clinical decision-making
Infection control	Essential complementary measure	Stewardship alone may not control MDRO transmission

10. Recommendations

Based on the findings of this review, strengthening antimicrobial stewardship in ICU settings requires coordinated clinical, organizational, and infection-control strategies. The following recommendations may enhance the effectiveness of ASPs and contribute to improved management of multidrug-resistant organisms (MDROs).

10.1 Strengthen Multidisciplinary Stewardship Teams

Hospitals should establish dedicated antimicrobial stewardship teams comprising intensivists, infectious disease specialists, clinical pharmacists, microbiologists, infection-control professionals, and nursing staff. Regular multidisciplinary review of antimicrobial therapy can improve prescribing quality and support timely treatment modification [2], [11].

10.2 Promote Guideline-Based Prescribing and De-escalation

Institution-specific antimicrobial guidelines should be developed using local microbiological and resistance data. Routine reassessment of empirical antibiotic therapy within the recommended clinical review period should be encouraged to facilitate appropriate de-escalation and avoid prolonged broad-spectrum antimicrobial exposure [6], [14].

10.3 Enhance Microbiological Surveillance and Diagnostic Support

Healthcare institutions should strengthen microbiological surveillance systems to monitor local resistance patterns and healthcare-associated infections. Timely laboratory reporting and effective communication between microbiology services and ICU clinicians can improve targeted antimicrobial therapy and stewardship decision-making [10], [24].

10.4 Continuous Education and Stewardship Monitoring

Regular education and training programs should be conducted to improve awareness of antimicrobial resistance, rational prescribing, and stewardship principles among healthcare professionals. Continuous monitoring through antimicrobial audits and feedback mechanisms can further improve compliance with stewardship practices and support long-term quality improvement [5], [30].

Table 5. Recommendations for Improving Antimicrobial Stewardship in ICUs

Recommendation	Primary Objective	Expected Benefit
Establish multidisciplinary ASP teams	Improve collaborative decision-making	Better antimicrobial optimization
Implement local prescribing guidelines	Standardize empirical and targeted therapy	Appropriate antibiotic selection
Promote routine antibiotic de-escalation	Reduce unnecessary broad-spectrum use	Lower antimicrobial selection pressure
Strengthen microbiological surveillance	Monitor resistance trends	Improved targeted treatment
Conduct regular antimicrobial audits	Evaluate prescribing practices	Enhanced stewardship compliance
Provide continuous clinician education	Improve stewardship awareness	Sustainable prescribing improvement
Integrate infection-control measures	Limit MDRO transmission	Better patient safety and resistance control

11. Future Scope

The future development of antimicrobial stewardship in ICU settings is expected to focus on more individualized, continuously monitored, and evidence-based antimicrobial management. Although conventional interventions such as audit and feedback, guideline-based prescribing, and de-escalation remain important, their effectiveness can be strengthened through improved clinical coordination and better use of available microbiological information [1], [2].

Further research should evaluate stewardship interventions across different ICU populations and healthcare settings to determine which strategies provide the most consistent benefits for antimicrobial optimization and MDRO control. Comparative studies involving different stewardship models may also help identify approaches that can be adapted to institutions with varying levels of resources and resistance patterns [11], [34].

Future investigations should place greater emphasis on the relationship between antimicrobial exposure and the development of resistant organisms. Long-term surveillance can help determine whether improvements in prescribing practices are sustained and whether they are accompanied by meaningful changes in MDRO occurrence and healthcare-associated infections [17], [31].

There is also scope for strengthening collaboration between antimicrobial stewardship and infection-prevention programs. Since resistant organisms are influenced by both antimicrobial selection pressure and transmission within healthcare environments, integrated approaches may provide greater long-term benefits than isolated stewardship interventions [22], [24].

Finally, future stewardship programs should develop standardized outcome measures that combine antimicrobial utilization, resistance patterns, patient safety, clinical outcomes, and economic considerations. Such comprehensive evaluation would allow healthcare institutions to determine the overall effectiveness and sustainability of ICU antimicrobial stewardship programs [7], [25], [36].

Table 6. Future Directions for ICU Antimicrobial Stewardship

Future Area	Potential Direction
Stewardship models	Development of adaptable ICU-specific ASP frameworks
MDRO surveillance	Long-term monitoring of resistance patterns
Antimicrobial optimization	Improved individualized treatment strategies
Diagnostic support	Faster integration of microbiological information
Infection prevention	Greater coordination between ASP and infection-control teams
Outcome assessment	Standardized clinical, microbiological, safety, and economic indicators
Research	Multicenter evaluation of sustainable stewardship approaches

12. Conclusion

Antimicrobial stewardship programs have become an important strategy for improving antimicrobial use and addressing the growing challenge of multidrug-resistant organisms in intensive care units. The evidence reviewed in this study indicates that interventions such as prospective audit and feedback, antimicrobial restriction, guideline-based prescribing, de-escalation, and multidisciplinary clinical review can improve the appropriateness of antimicrobial therapy [1], [2], [5].

The findings further indicate that effective stewardship can contribute to reducing unnecessary antimicrobial exposure and may support the control of important ICU-associated resistant organisms, including MRSA, VRE, CRE, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* [11], [17], [24]. However, antimicrobial stewardship alone cannot eliminate antimicrobial resistance. Its effectiveness is influenced by local resistance patterns, diagnostic capabilities, institutional resources, clinician participation, and infection-prevention practices. A successful ICU stewardship program should therefore balance the need for rapid and effective empirical treatment with timely reassessment and optimization of antimicrobial therapy. Continuous monitoring, multidisciplinary collaboration, antimicrobial surveillance, and evidence-based prescribing are essential for maintaining this balance [6], [12].

In conclusion, ASPs should be considered an integral component of ICU patient-safety and quality-improvement programs. Sustainable implementation can promote rational antimicrobial use, reduce unnecessary exposure, support MDRO control, and contribute to more efficient healthcare delivery. Continued evaluation and adaptation of stewardship strategies will be essential for preserving the effectiveness of existing antimicrobial therapies and improving outcomes for critically ill patients.

References

1. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional antimicrobial stewardship program. *Clin Infect Dis*. 2007;44(2):159–177.
2. Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: Guidelines by the IDSA and SHEA. *Clin Infect Dis*. 2016;62(10):e51–e77.
3. Dyar OJ, Huttner B, Schouten J, Pulcini C. What is antimicrobial stewardship? *Clin Microbiol Infect*. 2017;23(11):793–798.
4. Fishman N. Antimicrobial stewardship. *Am J Infect Control*. 2006;34(5):S55–S63.
5. Davey P, Marwick CA, Scott CL, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev*. 2017;2:CD003543.
6. Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on hospital antimicrobial stewardship objectives. *Lancet Infect Dis*. 2016;16(7):847–856.
7. Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Clinical and economic outcomes from antimicrobial stewardship programs. *Antimicrob Agents Chemother*. 2016;60(8):4840–4852.
8. MacDougall C, Polk RE. Antimicrobial stewardship programs in healthcare systems. *Clin Microbiol Rev*. 2005;18(4):638–656.
9. Dik JW, Poelman R, Friedrich AW, et al. An integrated stewardship model in hospitals. *Clin Microbiol Infect*. 2016;22:S81–S86.
10. Timbrook TT, Morton JB, McConeghy KW, et al. Impact of molecular rapid diagnostic testing on antimicrobial stewardship. *Clin Infect Dis*. 2017;64(1):15–23.
11. Bassetti M, Giacobbe DR, Vena A, et al. Challenges and solutions in antimicrobial stewardship in ICUs. *Curr Opin Crit Care*. 2019;25(5):463–470.
12. Kollef MH, Micek ST. Antimicrobial stewardship programs in intensive care units. *Crit Care Clin*. 2021;37(2):345–362.
13. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign guidelines 2021. *Intensive Care Med*. 2021;47(11):1181–1247.
14. Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed. *JAMA*. 2019;321(2):139–140.
15. Charani E, Holmes A. Antimicrobial stewardship programmes: The need for wider implementation. *BMJ*. 2013;346:f1493.
16. Howard P, Pulcini C, Hara GL, et al. An international cross-sectional survey of antimicrobial stewardship. *J Antimicrob Chemother*. 2015;70(4):1245–1255.
17. Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on antimicrobial resistance and infections. *Lancet Infect Dis*. 2017;17(9):990–1001.
18. Huttner B, Harbarth S, Carlet J, et al. Antimicrobial resistance: A global challenge. *Drug Resist Updat*. 2013;16(1-2):1–13.
19. Nathwani D, Sneddon J, Malcolm W, et al. Scottish Antimicrobial Prescribing Group. *J Antimicrob Chemother*. 2011;66(10):2355–2362.
20. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes. *Clin Infect Dis*. 2006;42(Suppl 2):S82–S89.
21. Rice LB. Federal funding for antimicrobial resistance research. *J Infect Dis*. 2008;197(8):1079–1081.
22. Vincent JL, Rello J, Marshall J, et al. International study of infection in ICUs. *JAMA*. 2009;302(21):2323–2329.
23. Magill SS, O'Leary E, Janelle SJ, et al. Changes in prevalence of healthcare-associated infections. *N Engl J Med*. 2018;379(18):1732–1744.
24. De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and stewardship in ICUs. *Intensive Care Med*. 2018;44(2):189–196.
25. Dik JW, Vemer P, Friedrich AW, et al. Financial evaluations of antimicrobial stewardship programs. *Antimicrob Resist Infect Control*. 2015;4:12.
26. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs. *Clin Infect Dis*. 2009;48(1):1–12.
27. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13(12):1057–1098.
28. WHO. Global Action Plan on Antimicrobial Resistance. Geneva: World Health Organization; 2015.
29. WHO. Antimicrobial Resistance: Global Report on Surveillance. Geneva: World Health Organization; 2014.
30. CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta: Centers for Disease Control and Prevention; 2019.

31. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of exposure to antipseudomonal beta-lactam antibiotics and development of resistance. *Clin Infect Dis*. 2019;68(10):1672–1679.
32. Weiss CH, Dibardino D, Rho J, Sung H, Collander B. Antibiotic stewardship in critical care. *Clin Chest Med*. 2016;37(4):779–789.
33. Patel SJ, Saiman L. Principles and strategies of antimicrobial stewardship. *Pediatr Clin North Am*. 2010;57(3):793–802.
34. Pulcini C, Binda F, Lamkang AS, et al. Developing core elements and checklist items for global hospital antimicrobial stewardship programs. *Clin Microbiol Infect*. 2019;25(1):20–25.
35. Tacconelli E, Carrara E, Savoldi A, et al. WHO priority pathogens list for research and development of new antibiotics. *Lancet Infect Dis*. 2018;18(3):318–327.
36. Dik JW, Hendrix R, Poelman R, et al. Measuring the impact of antimicrobial stewardship interventions. *Clin Microbiol Infect*. 2016;22(10):888–894.
37. Maseda E, Grau S, Luque S, et al. Antimicrobial stewardship in critically ill patients. *Med Intensiva*. 2015;39(1):44–56.
38. Kaki R, Elligsen M, Walker S, et al. Impact of antimicrobial stewardship in critical care. *J Antimicrob Chemother*. 2011;66(6):1223–1230.
39. Malani AN, Richards PG, Kapila S, et al. Clinical and economic outcomes from antimicrobial stewardship interventions. *Am J Infect Control*. 2013;41(2):145–148.
40. Goff DA, Kullar R, Goldstein EJC, et al. A global call from five countries to collaborate in antimicrobial stewardship. *Lancet Infect Dis*. 2017;17(2):e56–e63.